Semafore Broadens Pipeline With Multi-Targeted Kinase ...(aftmodels demonstrated 81 percent tumor ...),Health

"Semafore's proprietary kinase scaffold and our new multi-targeted kinase inhibitors add significant value to our pipeline," said Dr. Dennis McKeever, Semafore's Chief Executive Officer. "In addition to inhibiting all Class I isoforms of PI3K, our compounds SF2506 and SF2523 block additional key kinases which is in keeping with the multi-targeting philosophy behind other recent successful molecularly targeted agents."

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus -- cancer. Semafore is a leader in the development of PI3K inhibitors and one of the first biopharmaceutical companies to focus on both PI3K and PTEN. The company has successfully discovered and is developing a portfolio of drug candidates addressing these targets.

About SF1126

There is a strong and significant biological rationale for developing PI3 kinase inhibitors to treat cancer. Phosphoinositide 3-kinase (PI3K) is the gate keeper of one of the major pathways of intracellular signal transduction that regulates cell growth, proliferation, angiogenesis, migration, differentiation, and survival. Dysregulation of the PI3K signaling pathway is believed to play an integral role in the genesis of many cancers including both solid tumors and hematologic malignancies. Cancer research and pharmaceutical drug development efforts have been aimed at discovering and developing therapeutics that inhibit PI3K with the hope of controlling cancer cell division, angiogenesis (the formation of new blood vessels for cancer growth), proliferation and metastasis. Semafore's innovative PI3K inhibitor, SF1126, promises such hope for cancer patients. '/>"/>